# Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial

> **NCT07449910** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital of University of Science and Technology of China** · enrollment: 750 (estimated)

## Conditions studied

- Acute Ichemic Stroke
- Anterior Cerebral Artery Stroke
- Baricitinib

## Interventions

- **DRUG:** 2mg Baricitinib
- **DRUG:** 4mg Baricitinib
- **DRUG:** Placebo
- **OTHER:** Guideline-based therapy

## Key facts

- **NCT ID:** NCT07449910
- **Lead sponsor:** The First Affiliated Hospital of University of Science and Technology of China
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-17
- **Primary completion:** 2027-08-17
- **Final completion:** 2028-01-31
- **Target enrollment:** 750 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07449910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07449910, "Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07449910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*